Inclusion Criteria:

- All subjects were to be females 18 years of age or older who met the following
criteria:

1. The four normal subjects were to be normal, as established by medical history,
physical examination, and laboratory data, including CBC, serum chemistry, and
urinalysis.

2. The two subjects with obvious advanced stage ovarian cancer were to have either
histopathologically proven stage 3 or 4 disease or clinically obvious disease
defined by 2 of the following 3 conditions: (1) pelvic mass (2) omental
"caking", or (3) ascites.

3. Subjects were to have newly diagnosed, treatment refractory, or recurrent
disease. Subjects were to be treatment naïve or at least 2 months since last
non-surgical treatment. Subjects were to have normal kidney and liver function.

4. The two subjects with suspected ovarian cancer were to have a known mass.
Subjects were to have normal kidney and liver function.

5. Subjects were to provide informed consent prior to enrollment.

Exclusion Criteria:

- The following subjects were to be excluded:

1. Subject was pregnant or breast-feeding.

2. Subject was simultaneously participating in another investigative drug or device
study, or had completed follow-up phase of any previous study within 30 days
prior to enrollment in this study.

3. Subject had a known history of chronic abuse of drugs or alcohol or had tested
positive in the pre-study urine drug abuse screen.

4. Subject was currently taking folic acid supplements and could not stop taking
the supplements for a period of 3 days (2 days prior to the study and one day
after last imaging procedure).

5. Subject had physical condition that was unsuitable for radionuclide imaging.

6. Subject had been administered another radiopharmaceutical that would interfere
with the assessment of the biodistribution of Technetium Tc 99m EC20.